Overview
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2023-12-01
2023-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Ticagrelor, a direct-acting oral P2Y12-receptor antagonist, provides greater and more consistent platelet inhibition than clopidogrel. This study aimed to compare outcomes of ticagrelor plus aspirin versus clopidogrel plus aspirin 1 year after off-pump coronary artery bypass grafting (OPCAB) in patients with clopidogrel resistance.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Yonsei UniversityTreatments:
Clopidogrel
Ticagrelor
Criteria
Inclusion Criteria:1. patients aged 19 years or older
2. undergoing elective OPCAB surgery with multi-vessel coronary artery disease.
Exclusion Criteria:
1) patient had aspirin resistance